If you'd invested in: AstraZeneca and Mitie Group
Pharmaceutical giant AstraZeneca is expected to grow its earnings, while outsourcer Mitie's share rice has been hit by a series of profit warnings.
If only...
Pharmaceutical giant AstraZeneca (LSE: AZN) is expected to grow its earnings per share (EPS) in 2018, after four years of stagnant profits. Last month Astra reported that drug sales fell by 2% to $10bn (in constant currency terms) in the first half of 2018, while core operating profits were down 34% to $2.2bn. However, sales from new medicines rose by 69%, thanks largely to a strong performance from its cancer drugs including Tagrisso, which has benefited from its recent approval as the first-choice treatment for lung-cancer patients in Europe.
Be glad you didn't buy...
Mitie Group (LSE: MTO) provides services to owners and occupiers of commercial and industrial properties. The outsourcer, which was hit by several profit warnings and investigations by financial regulators last year, came under scrutiny after Carillion's collapse in January this year. However, in June it reported a pre-tax loss of £24.7m, down from £58.2m the previous year, while revenues rose 3.8% to £2.2bn. Mitie's chief executive Phil Bentley claims the firm's turnaround is on track and that it will return to profit this year as cost saving measures start to take effect.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Alice grew up in Stockholm and studied at the University of the Arts London, where she gained a first-class BA in Journalism. She has written for several publications in Stockholm and London, and joined MoneyWeek in 2017.
-
Christmas at Chatsworth: review of The Cavendish Hotel at Baslow
MoneyWeek Travel Matthew Partridge gets into the festive spirit at The Cavendish Hotel at Baslow and the Christmas market at Chatsworth
By Dr Matthew Partridge Published
-
Tycoon Truong My Lan on death row over world’s biggest bank fraud
Property tycoon Truong My Lan has been found guilty of a corruption scandal that dwarfs Malaysia’s 1MDB fraud and Sam Bankman-Fried’s crypto scam
By Jane Lewis Published
-
AstraZeneca’s Covid troubles could see it pull out of making vaccines
News AstraZeneca has suffered a series of setbacks with its Covid-19 jab and may exit the inoculation subsector altogether. Matthew Partridge reports
By Dr Matthew Partridge Published
-
AstraZeneca’s shareholders rebel over pay
News Shareholders in AstraZeneca have rebelled over proposals to raise bonus levels for its bosses.
By Dr Matthew Partridge Last updated
-
Major setback for AstraZeneca
Features Pharma giant AstraZeneca was banking on a key clinical trial for its cancer drugs. It was a flop. What comes next? asks Alice Gråhns.
By Alice Gråhns Published
-
A revolutionary new cancer treatment – and the blue-chip stock set to benefit
Features A new kind of cancer therapy could make a big difference to survival rates - and transform the fortunes of one big UK drugs company. Matthew Partridge explains.
By Dr Matthew Partridge Published
-
AstraZeneca fight rumbles on
News The proposed takeover of AstraZeneca is proving to be one of the most controversial yet.
By Cris Sholto Heaton Published
-
Company in the news: AstraZeneca
Features Drugs giant AstraZeneca is at the centre of a takeover tussle with US rival Pfizer. Phil Oakley looks at how the shares have been affected.
By Phil Oakley Published
-
Buy Big Pharma – the deal spree could be just beginning
Features With pharmaceutical stocks still looking cheap and some very smart deals being done, it’s a good time to buy in to the sector. John Stepek explains how.
By John Stepek Published